Nektar ($NKTR): What Do the New Durability Results Prove?

01 Scenarios: a funded Phase 3 program still needs decisive clinical evidence

Bull case: durability becomes a reproducible treatment advantage

Rezpegaldesleukin confirms the atopic dermatitis efficacy seen in Phase 2b and shows that less frequent maintenance can preserve meaningful disease control. The October 1, 2026 update adds a potential advantage in alopecia areata: five of eight qualifying responders maintained their hair-coverage response six months after treatment stopped. The favorable case requires that signal to survive much larger studies and a broader patient population, rather than relying on the selected responders who contributed to this small follow-up analysis. Source Source

Nektar has financing to pursue that test. Cash and short- and long-term marketable investments totaled $1,023.402 million at June 30, 2026; management’s August 13 forecast extended runway into the third quarter of 2028, beyond initial Phase 3 data expected in mid-2028. Successful enrollment, reproducible efficacy and an acceptable safety profile could therefore create value before another financing becomes necessary under the company’s plan. Those are clinical and operational conditions, not guaranteed outcomes. Source Source

Base case: development progresses while the market waits for stronger evidence

The atopic dermatitis program advances, but the next pivotal results remain distant and the alopecia evidence continues to generate debate. Nektar announced on October 1 that the third ZENITH AD study had started, while ZENITH AA was planned for early 2027. Starting the trials reduces execution uncertainty at the beginning of the process; it does not resolve the probability of positive results or approval. Source

Under this scenario, scientific presentations, recruitment progress and spending updates provide incremental information. The larger cash reserve supports the program, while the share count and expenses reflect the cost of getting there. The appropriate test is whether the company preserves its ability to reach the meaningful readouts and whether each new dataset strengthens the clinical case without changing denominators or overstating exploratory findings. Source Source

Bear case: the promising subsets do not translate into pivotal success

The Phase 3 dermatitis studies fail to reproduce the earlier benefit, or alopecia results remain too uncertain to establish a competitive treatment. The alopecia Phase 2b primary analysis at week 36 did not achieve statistical significance. Later extension and off-treatment findings support further development, but do not retrospectively turn that primary result into a successful endpoint. The larger program must answer the question directly. Source Source

An unsuccessful study could coincide with higher development spending and a need for additional capital. Even a positive trial might not demonstrate enough differentiation for broad adoption against established therapies. The downside would become more credible if enrollment slipped, safety concerns accumulated or the company repeatedly relied on selected analyses while the prespecified results remained weaker. Cash reduces immediate financing pressure; it does not insure the underlying drug against failure. Source Source

What Would Falsify This Reading

This reading recognizes meaningful dermatitis efficacy and financial capacity, while treating the alopecia durability signal and future pivotal success as uncertain. These developments would change the assessment.

• Pivotal results reproduce a useful clinical benefit. A clear Phase 3 result with an acceptable safety profile would strengthen the case. Failure to reproduce the dermatitis benefit or another weak primary alopecia result would undermine it. The Phase 2b evidence is not a substitute for those outcomes. Source Source Source
• Durability extends beyond a small selected group. Evidence that a substantial, well-defined population can sustain useful benefit would strengthen differentiation. Reliance on a handful of prior responders, without a convincing overall result, would weaken the broader commercial interpretation. Source Source
• Resources remain sufficient for the decisive readouts. Spending and recruitment consistent with reaching mid-2028 data would support management’s funding plan. Material delays or faster consumption requiring substantial additional dilution before the readouts would change the financial assessment. Source Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 The business: a development company centered on rezpegaldesleukin

Nektar Therapeutics is a clinical-stage biotechnology company listed on the Nasdaq Capital Market under NKTR. Its central asset is rezpegaldesleukin, also called REZPEG or NKTR-358, which the company wholly owns. The program spans atopic dermatitis, alopecia areata and an externally sponsored Type 1 diabetes study. These are development opportunities, not approved indications or established product sales. The financial figures in this page are U.S. dollars. Source Source

The mechanism is intended to stimulate regulatory T cells through the interleukin-2 receptor complex, helping restore immune regulation. Its commercial attraction is the possibility of controlling disease with a different approach and potentially durable benefit; clinical results must establish whether that biological rationale produces a treatment patients and physicians can use. Source Source

Nektar also describes earlier programs involving TNFR2 and a modified colony-stimulating factor protein. Those add research optionality, but the company’s near-term financial and clinical trajectory depends predominantly on rezpegaldesleukin. Treating each preclinical asset as a separate late-stage business would overstate diversification. Problems with the central program would still have a disproportionate effect on the investment case. Source

Reported revenue requires a further distinction. The June 2026 quarter’s $10.131 million consisted of non-cash royalty revenue related to rights previously sold. It is not revenue from commercial rezpegaldesleukin, and it does not represent a recurring cash stream available to pay current trial costs. The development business is funded primarily by its accumulated capital and investment resources. Source

03 The October 1 update: new evidence and a changed trial status

Nektar’s October 1, 2026 EADV update contains two different kinds of information. The clinical data concern durability and response during or after treatment. The operating update says the third Phase 3 ZENITH AD trial has been initiated and that the planned Phase 3 ZENITH AA study will begin in early 2027. Together, these developments do not establish pivotal efficacy. Source

The new dermatitis study includes patients previously exposed to systemic biologics or JAK inhibitors. That matters because the earlier Phase 2b induction evidence came from patients without prior JAK-inhibitor or biologic treatment. Demonstrating activity after other systemic therapies would broaden the potential clinical relevance, but it introduces a separate question that the earlier results cannot answer automatically. The initiation is now a stated company fact, replacing the earlier plan for a September start. Source Source

For alopecia, the small off-treatment cohort provides a reason to investigate whether benefit can persist after dosing stops. The strongest practical claim supported by the update is that some previous responders maintained their response. It is not evidence that most patients starting therapy will reach the same result, nor that patients can expect permanent remission. The denominator and the conditions for entering that analysis are essential to interpreting it. Source Source

The REZOLVE-AA Phase 2b study is listed as completed, with an actual completion date of August 20, 2026 in the registry record updated September 18. Publication of additional analyses does not mean the study remains an actively recruiting trial. The ongoing and planned Phase 3 programs are separate studies, with their own execution and efficacy risks. Source

04 Atopic dermatitis: the stronger primary efficacy foundation

The REZOLVE-AD publication in The Lancet in August 2026 reported 393 analyzed patients. At week 16, mean EASI improvement was 61% with 24 micrograms/kg every two weeks, 58% with 18 micrograms/kg every two weeks and 53% with 24 micrograms/kg every four weeks, versus 31% for placebo. The respective comparisons were statistically significant: p<0.0001, p<0.0001 and p=0.0002. This is the principal randomized efficacy foundation for advancing the dermatitis program. Source

The analysis included 104, 106 and 110 patients in the three active groups and 73 on placebo. EASI measures eczema severity; an average percentage improvement is not the percentage of patients who achieved clear skin. Keeping those concepts separate prevents an attractive mean change from being mistaken for a universal or near-universal response. The publication supports a treatment effect, while the magnitude of benefit for individual patients remains variable. Source

The safety results also need context. In the induction publication, injection-site reactions occurred in 223 of 320 active-treated patients, approximately 70%, versus three of 73 placebo patients, approximately 4%. Nearly all were mild to moderate and resolved. This is compatible with a tolerable treatment for many patients, but injection reactions remain relevant to adherence and patient preference. A larger and longer program is needed to characterize less common risks. Source

The primary result is more persuasive than an isolated biomarker finding or a comparison across unrelated trials. It still does not establish Phase 3 success. Different treatment history, longer observation and broader execution can alter the result. The investment question is whether the reproducible effect, maintenance schedule and safety can together support a differentiated approved product. Source Source

The placebo-adjusted induction differences are more informative than the active-arm means alone. Subtracting the 31% placebo improvement from the reported 61%, 58% and 53% active-arm improvements gives differences of approximately 30, 27 and 22 percentage points. These are differences in average percentage improvement in EASI, not additional percentages of patients cured. The publication reports corresponding confidence intervals of 18.0–41.3, 15.7–38.5 and 10.3–33.3 percentage points in favor of treatment. All exclude zero, supporting the induction signal. Their overlap does not establish that the highest dose is statistically superior to every other active regimen; that would require the relevant prespecified between-dose comparisons. Dose selection also incorporates exposure, safety and the maintenance strategy.

The publication distinguishes 398 enrolled patients from the 393 analyzed. The analysis excluded patients at two sites closed for Good Clinical Practice non-compliance; the sites received closure notification approximately 300 days before database lock. That disclosed rule belongs alongside the results rather than being confused with the separate post-hoc eligibility exclusion in alopecia. The dermatitis analysis used multiple imputation for missing observations. An imputed endpoint is a statistical estimate under stated assumptions, not a directly observed measurement from every participant. Understanding which patients entered each analysis and how missing observations were handled is necessary when comparing the published induction population with later maintenance responders.

05 Dermatitis maintenance: encouraging, but selected responders matter

The October 1, 2026 update describes sustained and deeper responses through week 52 with monthly and quarterly maintenance. Patients who entered maintenance had already shown a qualifying response during induction. This is useful evidence about maintaining benefit in responders, rather than a fresh randomized estimate of success for every patient beginning treatment. A favorable maintenance percentage is therefore not a substitute for an all-patient induction response rate. Source

Among all re-randomized patients in the highlighted 24-microgram/kg maintenance groups, complete skin clearance measured by EASI-100 increased from 4% to 22% with monthly treatment and from 9% to 18% with quarterly treatment between weeks 16 and 52. These results suggest that some patients continue to improve with longer treatment and less frequent dosing. They do not show that every participant can immediately move to the least frequent schedule. Source

For the commercial thesis, the relevant issue is the combination of depth, durability and treatment burden. A medicine that preserves disease control with fewer injections could be useful even without the highest initial response in every comparison. However, its practical place would depend on the approved label, safety, onset of action, physician experience, reimbursement and the performance of alternatives. Nektar’s maintenance findings support that opportunity; they do not settle those later decisions.

The next pivotal evidence must connect the induction benefit to a durable treatment strategy in the intended population. The October data are also not a new pivotal success simply because they were presented at a major congress. They are additional Phase 2b evidence, informing the Phase 3 development path. Source Source

The maintenance selection criterion was at least a 50% improvement in EASI after induction. Active-treated qualifying patients were re-randomized to dosing every four or twelve weeks; qualifying placebo recipients continued placebo to preserve blinding. Consequently, the move from 4% to 22% complete clearance in the monthly group is an 18-percentage-point improvement within a selected maintenance population, while 9% to 18% in the quarterly group is a nine-point change. Neither calculation estimates what fraction of all patients beginning induction would eventually achieve complete clearance on that schedule. Multiplying an induction response rate by a maintenance percentage would also be unreliable without matching the exact populations, missing-data rules and endpoint definitions.

06 Alopecia: the original primary endpoint remains the critical qualification

The EADV 2026 REZOLVE-AA presentation also provides alopecia-specific safety data for the overall safety-analysis period: injection-site reactions affected 66 of 72 rezpegaldesleukin recipients (91.7%), compared with 6 of 20 placebo recipients (30.0%). Infections and infestations occurred in 35 of 72 (48.6%) versus 9 of 20 (45.0%). These are separate from the dermatitis safety population. Frequency should be read alongside severity and treatment persistence: the presentation reports that nearly all adverse events were mild to moderate, one patient had a severe injection-site reaction and continued treatment, and no patient stopped treatment because of an injection-site reaction over 52 weeks. Overall adverse-event-related discontinuation among exposed patients was 1.4%. High local-reaction frequency can matter to treatment burden without proving a serious systemic safety signal. EADV 2026: rezpegaldesleukin in REZOLVE-AA (PDF).

The December 16, 2025 REZOLVE-AA announcement reported 92 patients in the primary analysis: 35 at the higher dose, 37 at the lower dose and 20 on placebo. Mean SALT reduction at week 36 was 28.2% with 24 micrograms/kg and 30.3% with 18 micrograms/kg, versus 11.2% with placebo. The p-values were 0.186 and 0.121, respectively. Neither comparison met conventional statistical significance for the primary endpoint. Source

After excluding four patients with major eligibility violations, the reported reductions were 29.6% and 30.4% versus 5.7% for placebo, with p-values of 0.049 and 0.042. That supporting analysis can help assess the biological signal, but its different population matters. It should not replace the original result or be described as if the full primary analysis had succeeded. The appropriate conclusion is a signal requiring stronger confirmation. Source

The later extension also involved a smaller, selected population. Thirty-one patients entered, including 14 in the lower-dose group, 13 in the higher-dose group and four on placebo. Between weeks 36 and 52, new SALT scores of 20 or less were achieved by 29% at the lower dose and 31% at the higher dose, versus none among the continuing placebo patients. SALT of 20 or less corresponds to at least 80% scalp-hair coverage. Source Source

The October presentation reports overall week-52 SALT≤20 response rates of 25.8% at the lower dose and 27.6% at the higher dose, versus 6.7% with placebo; the high-dose comparison shown has p=0.049 in the modified analysis excluding eligibility violations. That modified analysis carried week-36 values forward for patients who did not enter the extension and used multiple imputation for missing observations. It is therefore not a simple observed responder fraction among all originally randomized patients. This supports continued development, but cannot erase the limitations of the earlier primary result or the small extension. Source

07 Off-treatment hair regrowth: read five of eight before reading 63%

The new October 1, 2026 disclosure reports that six of eight qualifying week-52 responders maintained SALT≤20 after four months without treatment, and five of eight after six months. The corresponding percentages are 75% and approximately 63%. These are response-maintenance figures among a small group that had already achieved the threshold, not success rates for all 92 patients in the original analysis or all 27 actively treated extension participants. Source Source

A separate result concerned near-complete scalp coverage, SALT≤10. Among the 27 active-treated patients entering the extension, that response rose from 7% at week 52 to 19% after six months off treatment. This uses a different denominator and endpoint. It suggests further improvement in a subset, while still leaving considerable uncertainty about how often the effect would occur in a larger population. Source

The distinction is material for a trader evaluating a durability headline. Losing the response in several patients can change a percentage sharply when the denominator is this small. The company’s presentation also includes comparisons with baricitinib from different studies, with different analytical handling. Those are not head-to-head results and cannot establish superiority. The more convincing next step is confirmation within Nektar’s own adequately sized pivotal trial. Source

The evidence is therefore neither meaningless nor definitive. It gives a reason to test longer treatment and durability, while leaving unanswered how many unselected patients benefit, how long benefit lasts and how the overall treatment compares with available options. The Phase 3 plan must convert this hypothesis into a clear result rather than merely reproduce another favorable small subset. Source Source

One patient represents 12.5 percentage points in an eight-person denominator. The reported five of eight is exactly 62.5%, rounded to 63%; four of eight would be 50%, and six of eight 75%. This arithmetic illustrates sensitivity to individual outcomes, not a forecast that any particular patient will lose response. The presentation states that all eight were available for off-treatment assessments, making its non-responder-imputation analysis identical to an observed analysis for this particular cohort. That completeness is useful, but it does not remove selection: these patients had already responded after the extension. A larger prospective population could produce a materially different maintenance estimate even with the same underlying mechanism.

The presentation also reports a different durability question in 21 patients with observed six-month follow-up: 48% had no worsening of their week-52 SALT score. This is not the same endpoint as retaining SALT of 20 or less in the eight qualifying responders. A patient can maintain an unchanged score above 20, or worsen slightly while remaining below 20. The 21-person observed denominator also differs from the 27 active-treated extension entrants used for the SALT-of-10 analysis. Those three views answer different questions about stability, response thresholds and missing follow-up. They do not add up to one response rate, and not all participants achieved the same degree of scalp coverage.

08 Next catalysts: Phase 3 execution and the path to 2028

The next stated development milestone is initiation of the 850-patient ZENITH AA Phase 3 study in early 2027, according to the October 1 update. The planned primary assessment is SALT≤20 at week 52. Early 2027 is a company window, not a fixed launch day, and initiating enrollment is distinct from completing treatment and producing results. Passing the first milestone requires a trial actually underway; the value-defining test comes later. Source

In atopic dermatitis, the October update confirms that all three planned ZENITH AD studies have now been initiated. Management’s August 13 roadmap anticipated initial Phase 3 data in mid-2028 and a first biologics license application in 2029. These are development expectations conditional on enrollment, execution, safety and efficacy. They are not a filing acceptance, a regulatory review deadline or an approval date. Source Source

The October presentation also identifies an ongoing TrialNet-sponsored Type 1 diabetes study, with initial data expected in 2027. That program provides another potential clinical observation, but it does not have the same maturity as the pivotal dermatitis studies. Its relevance depends on the actual result and what further development would be required. Earlier discovery programs remain further from a decision on commercial value. Source

Between these milestones, the useful disclosures are recruitment progress, manufacturing readiness, spending and any material safety information. The company is dependent on external clinical and manufacturing partners, including supply of the PEG reagent used in rezpegaldesleukin. Cash availability helps fund execution, but cannot eliminate delays or quality problems in those activities. Source

09 Biomarkers and differentiation: support for a thesis, not a substitute endpoint

The September 30, 2026 biomarker update examined a subset of 100 dermatitis patients: 59 treated at the planned Phase 3 dose and 41 on placebo. Early molecular changes were associated with later clinical improvement, and the reported correlations in treated patients had p-values below 0.001. This supports the proposition that the drug engages relevant biology, but association within a substudy does not establish an additional approved benefit or replace a randomized clinical endpoint. Source Source

The commercial question is whether the clinical profile can justify another systemic treatment in competitive markets. Atopic dermatitis already has effective therapies and extensive physician experience. Alopecia offers a different opportunity, but the Phase 2b results are less definitive. A novel mechanism can matter when it produces an observable advantage in efficacy, tolerability, durability or convenience; novelty by itself is not sufficient.

The evidence supports discussing less frequent dosing and off-treatment durability as hypotheses with clinical observations behind them. It does not support saying that rezpegaldesleukin cures the disease, permanently resets immunity or has already displaced existing drugs. The same restraint applies to broad extrapolations from biomarkers into other diseases. Each indication requires its own useful clinical result. Source Source

For valuation, this means the program can have substantial upside without assigning full commercial success to every indication. The most credible progress would be a stronger clinical package accompanied by a feasible regulatory path and a treatment profile that remains useful against the alternatives available when it reaches the market. Source

The molecular cohort contained 100 of the 393 analyzed induction patients, approximately 25.4%. Its 59 active-treated and 41 placebo participants therefore provide a substudy rather than a replacement for the larger randomized efficacy analysis. The presentation used different thresholds for transcriptomic and proteomic changes and examined multiple pathways. A correlation between early biomarker movement and later EASI improvement supports a biological association; it does not show that changing that biomarker necessarily causes improvement or reliably predicts an individual patient’s outcome. Nor do skin signatures associated with cardiovascular disease establish a reduction in heart attacks. Those broader clinical claims would require their own outcomes, populations and prospective evaluation.

10 Cash, monthly burn and management’s runway forecast

At June 30, 2026, Nektar held $39.267 million cash and equivalents, $645.074 million short-term investments and $339.061 million long-term investments. The combined marketable resource total was $1,023.402 million. Cash plus short-term investments alone was $684.341 million. These distinctions matter: the complete balance is broader than cash in the bank, while omitting the marketable portfolio would understate the resources available to fund development. Source

Operating cash use in the first half of 2026 was $120.068 million, or a calculated $20.011 million per month. Including $0.112 million of equipment purchases gives $120.180 million, equivalent to $20.030 million per month. A static calculation using the complete cash-and-investment balance gives about 51.1 months at that historical rate; using cash and short-term investments alone gives about 34.2 months. Neither is management guidance or an October balance forecast. Source

Management’s actual August 13 forecast extended funding into the third quarter of 2028. That is more relevant to the planned program than assuming first-half spending stays constant as additional Phase 3 activity ramps. R&D expense increased to $39.129 million in the June quarter from $29.886 million a year earlier, and clinical manufacturing and study activity can raise spending further. A well-funded starting position still needs monitoring against the pivotal timetable. Source Source

Prepaid research and development expenses were $48.150 million current and $8.669 million long-term at June 30, 2026. Those payments help explain why cash use differs from the income-statement loss. They may support future work, but cannot also be counted as unspent cash. The next quarterly comparison should connect enrollment, development commitments and the movement of the liquid portfolio. Source

A spending sensitivity makes the gap between historical arithmetic and management guidance tangible. At 25% above the first-half operating-plus-capex rate, monthly use would be about $25.04 million and the June total would cover approximately 40.9 months. At 50% above that rate, monthly use would be $30.045 million and coverage approximately 34.1 months. Both quotients start at June 30 and ignore subsequent cash flows; neither is remaining runway at the editorial date. They also treat the investment portfolio as available without modeling its maturity schedule or returns. Management’s shorter forecast incorporates a developing clinical plan that these static calculations do not, so the larger arithmetic number must not override the company’s spending assumptions.

Prepaid research spending helps reconcile the difference between expense and cash consumption. Current and long-term research prepayments together increased from $20.784 million at December-end to $56.819 million at June-end, a $36.035 million change. That balance-sheet movement is not a complete cash-flow bridge, because other assets, accruals and noncash adjustments also changed. It does demonstrate why simply dividing cash by the income-statement loss could overstate coverage when trial services are paid in advance. Conversely, consumption of previously prepaid services could create expense without an equivalent new cash payment in a later quarter. Tracking both the prepaid balance and operating cash flow makes the Phase 3 spending ramp easier to interpret.

11 Financing, shares and the remaining dilution channels

The June 30, 2026 balance sheet reported 34,129,664 common shares, compared with 20,378,832 at December 31, 2025: a calculated increase of approximately 67.5%. The August 7 cover-date count was 34,142,994. This financing materially improved Nektar’s ability to fund the clinical program, while spreading future value over a much larger share base. A growing cash total and dilution are two sides of the same transactions. Source

The February 2026 offering raised approximately $431.9 million net, and the April offering approximately $350.4 million net. Additional ATM sales in February through early April generated approximately $106.6 million net. The old ATM programs and associated April 2025 shelf were exhausted, but a new $150 million ATM established in May 2026 was unused at June 30. The newer automatic shelf permits an unspecified amount of securities, subject to the applicable offering framework. Source

The pre-funded warrants issued in February were exercised in June, producing 293,100 common shares; no shares remained issuable under that series at June 30. They are already accounted for and do not represent additional outstanding warrant dilution. The authorized common-share ceiling was 390 million, separate from issued shares, and shareholders approved another three million shares for the incentive plan in June. Authorization and plan capacity are not cash receipts or current float. Source

Further employee awards remain a dilution channel. The September 25, 2026 announcement disclosed grants made September 18 of 58,600 options and 2,450 RSUs to new employees. These are compensation rights with their own vesting and exercise terms. Their economic effect should be considered alongside actual issuance, rather than assuming the June share count remains permanent. Source

The share-count increase and the ownership effect have different denominators. June common shares exceeded December common shares by 13,750,832, an increase of approximately 67.5% relative to the opening count. A holder keeping the same number of shares throughout, without buying or selling, would retain about 59.7% of their former proportional ownership, a reduction of approximately 40.3%. That does not mean the investment’s value fell by 40.3%, because the company also received substantial new capital and its market price changed. It is a way to describe the ownership consequence without conflating dilution with a realized trading loss or assuming that financing proceeds created equivalent value for every holder.

An illustrative use of the unused $150 million ATM at the dated $46.99 reference price would issue about 3.192 million shares before considering execution prices. Relative to the August cover count of 34.143 million, that is approximately 9.4% additional shares; the old common block would represent about 91.5% of the enlarged denominator. At the stated 3% commission, gross proceeds of $150 million would leave $145.5 million before other offering expenses. This is capacity arithmetic, not an announcement or expected transaction. Actual proceeds, pricing, fees and issuance could differ, and the June filing’s unused status does not establish what happened after quarter-end.

12 Obligations and litigation: the verdict is not collected cash

At June 30, 2026, liabilities related to previously sold future royalties were $57.378 million. Nektar accounts for those transactions as debt and recognizes non-cash royalty revenue and interest over their life. The accounting balance and imputed interest are not equivalent to a conventional bank loan requiring the same amount of current cash interest. Lease liabilities were a further $78.556 million, combining current and non-current portions. These obligations prevent a simplistic description of the company as having no financial commitments. Source

The capital structure is nevertheless principally equity-funded. Current development capacity depends on the investment portfolio, actual cash expenditure and the terms of any future financing. If new borrowing were introduced, its repayment schedule and covenants would need to be assessed separately. Historical non-cash royalty accounting neither inflates operating cash generation nor implies a conventional debt-service schedule. Source

On September 24, 2026, a jury found that Lilly breached the implied covenant of good faith and fair dealing in the former collaboration agreement and awarded Nektar $90 million in damages, with interest to be determined by the court. Nektar reported the verdict in its September 25 filing. The verdict remains subject to post-trial proceedings and any resulting judgment may be appealed. Source

The potential recovery is material, but adding it to June cash or treating it as an immediate financing receipt would be incorrect. The next meaningful legal developments concern the post-trial outcome, judgment, any appeal and eventual collection. A favorable verdict is a separate asset-related development; it neither proves the drug works nor removes the clinical risks of the remaining program. Source

The $90 million verdict is equivalent to roughly 4.5 months of the historical $20.030 million operating-plus-capex rate, or approximately 8.8% of June cash and investments. These comparisons describe scale only. They do not assign a probability of collection, estimate legal costs or taxes, include interest, or imply that the money arrived when the jury returned its verdict. Clinical funding should continue to be assessed from reported resources and disclosed plans until a later filing establishes recognition and receipt. The same separation prevents the opposite error: an appeal affecting a potential recovery would not, by itself, reverse the Phase 2 efficacy observations or determine the outcome of a pivotal trial.

13 Ownership, short positioning and the final trading checklist

Two Seas reported 3,345,978 shares, or 9.8%, with a September 25, 2026 event date in its September 28 amendment. Its affiliated reporting entities refer to the same underlying position, not several holdings to add together. This newer disclosure supersedes the older June snapshot for that manager. Ownership information carries its actual reporting date and is not a live portfolio. Source

August 20 filings report August 18 sales of 418 shares by CEO Howard Robin and 186 by chief R&D officer Jonathan Zalevsky. The footnotes explicitly identify tax withholding associated with RSU vesting and state that the transactions were not discretionary trades. They should therefore not be used as evidence of a voluntary bearish management call. Source Source

Finviz data as of October 2, 2026 showed 33.06 million float, 17.35% short float and a short ratio of 6.18. Its institutional ownership figure was 104.67%, a problematic third-party total that is not a literal, consistent ownership table. The short-interest settlement date is not stated. These figures come from a third-party snapshot; they are not positions newly measured on that day. Source

The practical checklist is clinical before it is promotional: retain the missed full alopecia primary endpoint, the small off-treatment denominator, the stronger dermatitis randomized result and the separate Phase 3 timelines. Then compare spending and shares with the resources required to reach those milestones. Nektar is better financed and further into development; a successful commercial drug still depends on pivotal evidence, regulatory review and eventual adoption. Source Source Source Source